Correlation Between Pmv Pharmaceuticals and NLS Pharmaceutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Pmv Pharmaceuticals and NLS Pharmaceutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Pmv Pharmaceuticals and NLS Pharmaceutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Pmv Pharmaceuticals and NLS Pharmaceutics AG, you can compare the effects of market volatilities on Pmv Pharmaceuticals and NLS Pharmaceutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Pmv Pharmaceuticals with a short position of NLS Pharmaceutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Pmv Pharmaceuticals and NLS Pharmaceutics.

Diversification Opportunities for Pmv Pharmaceuticals and NLS Pharmaceutics

0.65
  Correlation Coefficient

Poor diversification

The 3 months correlation between Pmv and NLS is 0.65. Overlapping area represents the amount of risk that can be diversified away by holding Pmv Pharmaceuticals and NLS Pharmaceutics AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on NLS Pharmaceutics and Pmv Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Pmv Pharmaceuticals are associated (or correlated) with NLS Pharmaceutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of NLS Pharmaceutics has no effect on the direction of Pmv Pharmaceuticals i.e., Pmv Pharmaceuticals and NLS Pharmaceutics go up and down completely randomly.

Pair Corralation between Pmv Pharmaceuticals and NLS Pharmaceutics

Given the investment horizon of 90 days Pmv Pharmaceuticals is expected to under-perform the NLS Pharmaceutics. But the stock apears to be less risky and, when comparing its historical volatility, Pmv Pharmaceuticals is 3.85 times less risky than NLS Pharmaceutics. The stock trades about -0.16 of its potential returns per unit of risk. The NLS Pharmaceutics AG is currently generating about 0.01 of returns per unit of risk over similar time horizon. If you would invest  186.00  in NLS Pharmaceutics AG on December 26, 2024 and sell it today you would lose (32.00) from holding NLS Pharmaceutics AG or give up 17.2% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Pmv Pharmaceuticals  vs.  NLS Pharmaceutics AG

 Performance 
       Timeline  
Pmv Pharmaceuticals 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Pmv Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unfluctuating performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in April 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.
NLS Pharmaceutics 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in NLS Pharmaceutics AG are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Even with relatively unfluctuating basic indicators, NLS Pharmaceutics may actually be approaching a critical reversion point that can send shares even higher in April 2025.

Pmv Pharmaceuticals and NLS Pharmaceutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Pmv Pharmaceuticals and NLS Pharmaceutics

The main advantage of trading using opposite Pmv Pharmaceuticals and NLS Pharmaceutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Pmv Pharmaceuticals position performs unexpectedly, NLS Pharmaceutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NLS Pharmaceutics will offset losses from the drop in NLS Pharmaceutics' long position.
The idea behind Pmv Pharmaceuticals and NLS Pharmaceutics AG pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Complementary Tools

Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Global Correlations
Find global opportunities by holding instruments from different markets
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Volatility Analysis
Get historical volatility and risk analysis based on latest market data